Ro

Preparation / pathway

ED tablets and compounded Sparks / Daily Rise Gummies

Published price

Selected initial and renewal quote required

Conditions to confirm

Keep promotional pricing separate from the continuing offer. Confirm formulation, quantity, billing interval and follow-up arrangements.

Different preparations occupy the menu

Ro describes conventional ED tablets along with Sparks and Daily Rise Gummies. The latter products are described as compounded preparations. A review should preserve those distinctions rather than presenting every item as an interchangeable approved tablet. [Ro ED page]

Request the complete medicine identity for the selected prescription: ingredients, amounts, formulation and directions. Bring existing ED treatments into the assessment too. Include products used occasionally or obtained from another prescribing service. A different brand or delivery format does not establish that ingredients will not overlap.

The commercial record remains product-specific

The public information retained for this review does not establish one continuing price across Ro's ED options. Ask for the actual first charge and future charges, including the supplied quantity and any commitment behind a promotion. Do not turn a first-order discount into an assumed annual cost.

Confirm how to manage scheduled orders while a clinical question is being reviewed. A customer-service process for billing may differ from access to the prescribing professional. This publication has not used Ro's patient service or measured its fulfillment and support performance.

The clinical record needs separate evidence

FDA does not approve compounded drugs, and ingredient evidence does not independently validate a mixture's clinical result. The Viagra label cautions against using it with other PDE5 inhibitors or ED therapies. Ask the clinician how relevant warnings and alternatives apply to the proposed product. [FDA] [Label]

NIDDK describes assessment and treatment approaches that extend beyond an online menu. Ask where to go if examination, further investigation or another treatment category is indicated. Our wider-options guide and claim-review guide help frame those questions. Ro is listed as an additional care option, not a clinically scored winner or a product tested by this publication. [Diagnosis] [Treatments]